Following on from advice received from the company, NICE has decided to suspend this appraisal whilst the company confirm their regulatory filing plans in the UK. As this appraisal has been deferred NICE will continue to monitor any development and will update interested parties if the situation changes.

Status:
Suspended
Technology type:
Medicine
Decision:
Prioritised
Process:
TA
ID number:
3922

Email enquiries

If you have any queries please email scheduling@nice.org.uk

Timeline

Key events during the development of the guidance:

Date Update
16 February 2024 Suspended. Following on from advice received from the company, NICE has decided to suspend this appraisal whilst the company confirm their regulatory filing plans in the UK. As this appraisal has been deferred NICE will continue to monitor any development and will update interested parties if the situation changes.
26 January 2023 Note added to the project documents

For further information on our processes and methods, please see our CHTE processes and methods manual